Deepak L. Bhatt
Dr. Deepak L. Bhatt is a prominent cardiologist and the director of the Mount Sinai Fuster Heart Hospital, as well as a professor at the Icahn School of Medicine. He is known for his significant contributions to cardiovascular research, particularly in the field of diabetes and its impact on heart health. Recently, he was noted in the news for his role as the study chair in groundbreaking research published in The Lancet, which highlighted the cardiovascular benefits of sotagliflozin, a newly approved medication for type 2 diabetes and chronic kidney disease that also significantly reduces the risk of heart attacks and strokes.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| United States | 1 | 7.00 | 0.02% | +0% | 331,002,651 | 72,748 | $21,000,000 | 4,615$ |
| Totals | 1 | 331,002,651 | 72,748 | $21,000,000 | 4,615$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United States:
Dr. Deepak L. Bhatt, director of Mount Sinai Fuster Heart Hospital and a professor of cardiovascular medicine at Icahn School of Medicine at Mount Sinai in New York, commented on the genetic factors of lipoprotein(a).
7
Brazil:
Deepak L. Bhatt is the director of the Mount Sinai Fuster Heart Hospital and the leader of the study on sotagliflozina.
9
India:
Dr. Deepak L. Bhatt is the study chair and director of Mount Sinai Fuster Heart Hospital, who discussed the benefits of sotagliflozin in reducing heart attack and stroke risk.
9